Benzimidazole Derivatives as Kinase Inhibitors

被引:31
作者
Garuti, Laura [1 ]
Roberti, Marinella [1 ]
Bottegoni, Giovanni [2 ]
机构
[1] Univ Bologna, Dept Pharm & Biotechnol, I-40126 Bologna, Italy
[2] Italian Inst Technol, Dept Drug Discovery & Dev, I-16163 Genoa, Italy
关键词
ATP-competitive; benzimidazole; biological activity; kinase inhibition; multi-target inhibitor; SAR; selectivity; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; POTENT AURORA KINASE; SELECTIVE INHIBITORS; CK2; INHIBITORS; BIOLOGICAL EVALUATION; CANCER; DISCOVERY; DESIGN; AT9283; ZSTK474;
D O I
10.2174/0929867321666140217105714
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Benzimidazole is a common kinase inhibitor scaffold and benzimidazole-based compounds interact with enzymes by multiple binding modes. In some cases, the benzimidazole acts as part of the hinge-binding motif, in others it has a scaffolding role without evidence for direct hinge binding. Several of these compounds are ATP-competitive inhibitors and show high selectivity by exploiting unique structural properties that distinguish one kinase from the majority of other kinases. However, the high specificity for a single target is not always sufficient. Thus another approach, called multi-target therapy, has been developed over the last few years. The simultaneous inhibition of various kinases may be useful because the disease is attacked at several relevant targets. Moreover, if a kinase becomes drug-resistant, a multi-targeted drug can act on the other kinases. Some benzimidazole derivatives are multi-target inhibitors. In this article benzimidazole inhibitors are reported with their mechanisms of action, structure-activity relationship (SAR) and biological properties.
引用
收藏
页码:2284 / 2298
页数:15
相关论文
共 70 条
[1]   Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles [J].
Arienti, KL ;
Brunmark, A ;
Axe, FU ;
McClure, K ;
Lee, A ;
Blevitt, J ;
Neff, DK ;
Huang, LM ;
Crawford, S ;
Pandit, CR ;
Karlsson, L ;
Breitenbucher, JG .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) :1873-1885
[2]  
Barot KP, 2013, MINI-REV MED CHEM, V13, P1421
[3]   Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole [J].
Battistutta, R ;
Mazzorana, M ;
Sarno, S ;
Kazimierczuk, Z ;
Zanotti, G ;
Pinna, LA .
CHEMISTRY & BIOLOGY, 2005, 12 (11) :1211-1219
[4]  
Blaszczak-Swiatkiewicz K, 2013, ACTA POL PHARM, V70, P451
[5]   Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond [J].
Bologna, M. ;
Vicentini, C. ;
Muzi, P. ;
Pace, G. ;
Angelucci, A. .
CURRENT MEDICINAL CHEMISTRY, 2011, 18 (19) :2827-2835
[6]   Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors [J].
Buchstaller, Hans-Peter ;
Burgdorf, Lars ;
Finsinger, Dirk ;
Stieber, Frank ;
Sirrenberg, Christian ;
Amendt, Christiane ;
Grell, Matthias ;
Zenke, Frank ;
Krier, Mireille .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (08) :2264-2269
[7]   Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kβ Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers [J].
Certal, Victor ;
Halley, Frank ;
Virone-Oddos, Angela ;
Delorme, Cecile ;
Karlsson, Andreas ;
Rak, Alexey ;
Thompson, Fabienne ;
Filoche-Romme, Bruno ;
El-Ahmad, Youssef ;
Carry, Jean-Christophe ;
Abecassis, Pierre-Yves ;
Lejeune, Pascale ;
Vincent, Loic ;
Bonnevaux, Helene ;
Nicolas, Jean-Paul ;
Bertrand, Thomas ;
Marquette, Jean-Pierre ;
Michot, Nadine ;
Benard, Tsiala ;
Below, Peter ;
Vade, Isabelle ;
Chatreaux, Fabienne ;
Lebourg, Giles ;
Pilorge, Fabienne ;
Angouillant-Boniface, Odile ;
Louboutin, Audrey ;
Lengauer, Christoph ;
Schio, Laurent .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (10) :4788-4805
[8]   In silico binding free energy predictability with π-π interaction energy-augmented scoring function: Benzimidazole Raf inhibitors as a case study [J].
Chung, Jae Yoon ;
Cho, Seung Joo ;
Cho, Art E. ;
Hah, Jung-Mi .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (09) :3278-3283
[9]   Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases [J].
Cozza, Giorgio ;
Sarno, Stefania ;
Ruzzene, Maria ;
Girardi, Cristina ;
Orzeszko, Andrzej ;
Kazimierczuk, Zygmunt ;
Zagotto, Giuseppe ;
Bonaiuto, Emanuela ;
Di Paolo, Maria Luisa ;
Pinna, Lorenzo A. .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2013, 1834 (07) :1402-1409
[10]   ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo [J].
Dan, Shingo ;
Okamura, Mutsumi ;
Mukai, Yumiko ;
Yoshimi, Hisashi ;
Inoue, Yasumichi ;
Hanyu, Aki ;
Sakaue-Sawano, Asako ;
Imamura, Takeshi ;
Miyawaki, Atsushi ;
Yamori, Takao .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (06) :936-943